DERMATOP® Emollient Cream (prednicarbate emollient cream) 0.1% contains prednicarbate, a synthetic corticosteroid for topical dermatologic use. Topical corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.
Each gram of DERMATOP Emollient Cream 0.1% contains 1.0 mg of prednicarbate.
DERMATOP Emollient Cream 0.1% is a medium-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. DERMATOP Emollient Cream 0.1% may be used with caution in pediatric patients 1 year of age or older. The safety and efficacy of drug use for longer than 3 weeks in this population have not been established. Since safety and efficacy of DERMATOP Emollient Cream 0.1% have not been established in pediatric patients below 1 year of age, its use in this age group is not recommended.
Media Articles Related to Dermatop ( Topical)
Unlikely that topical pimecrolimus associated with increased risk of cancer
Source: Dermatology News From Medical News Today [2015.02.20]
The topical medicine pimecrolimus to treat eczema (atopic dermatitis or AD) in children appears unlikely to be associated with increased of risk of cancer based on how it was used in group of...
FDA Approves 1st Topical Gel to Ease Redness of Rosacea
Source: MedicineNet brimonidine Specialty [2013.08.28]
Title: FDA Approves 1st Topical Gel to Ease Redness of Rosacea
Category: Health News
Created: 8/27/2013 12:35:00 PM
Last Editorial Review: 8/28/2013 12:00:00 AM
Burn Risk Seen with Topical Pain Relievers
Source: MedPage Today Product Alert [2012.09.13]
WASHINGTON -- The FDA warned Thursday of the risks of rare but serious chemical burns with certain over-the-counter topical pain relievers, including Bengay, Capzasin, Flexall, Icy Hot, and Mentholatum.
Vitaros® (alprostadil), the first cream to treat men with erectile dysfunction, is now available for prescription in the UK
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2014.06.17]
The first topical cream approved for the treatment of erectile dysfunction (ED) in men over the age of 18 years, Vitaros® (topical alprostadil cream), is now available for prescription in the...
Published Studies Related to Dermatop ( Topical)
Effectiveness of topical curcumin for treatment of mastitis in breastfeeding
women: a randomized, double-blind, placebo-controlled clinical trial. 
inflammation in women suffering from lactational mastitis... CONCLUSION: The results of the current study indicate that topical preparation of
"Coffee plus honey" versus "topical steroid" in the treatment of
chemotherapy-induced oral mucositis: a randomised controlled trial. 
steroid, honey, honey plus coffee) in patients suffering from oral mucositis... CONCLUSION: Oral mucositis can be successfully treated by a combination of honey
Topical tetracaine used for 24 hours is safe and rated highly effective by
patients for the treatment of pain caused by corneal abrasions: a double-blind,
randomized clinical trial. 
of pain caused by corneal abrasions... CONCLUSIONS: Topical tetracaine used for 24 hours is safe, and while there was no
Efficacy and safety of topical Trikatu preparation in, relieving mosquito bite
reactions: a randomized controlled trial. 
mosquito bite reactions... CONCLUSION: Trikatu did not show additional effects for relieving mosquito bite
A phase III randomized, placebo-controlled study of topical amitriptyline and
ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of
Rochester CCOP study of 462 cancer survivors. 
efficacy of 2% ketamine plus 4% amitriptyline (KA) cream for reducing CIPN... CONCLUSIONS: This study suggests that KA cream does not decrease CIPN symptoms in
Clinical Trials Related to Dermatop ( Topical)
Standardized Time- and Score-Oriented Treatment of Moderate and Severe Atopic Dermatitis [Completed]
The study was designed to test the hypothesis whether a standardized, time-and score-oriented
treatment following a strict evidence based algorithm is equally effective to a standard
treatment regimen for moderate to severe atopic dermatitis.
Study Type: Mono-centre study, patients are blinded, physicians are randomized to either
treat study- or controll group
Eligible are patients age 2 years or older with SCORAD >= 20 Duration: 12 Months, study
visits every 4 weeks.
Primary endpoint is Difference between Baseline SCORAD and mean SCORAD under treatment.
Secundary endpoints are quality of life, safety and economic burden in both treatment
Fexofenadine in Pruritic Skin Disease [Completed]